Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study

Author： Florentin M Liberopoulos EN Filippatos TD Kostara C Tselepis A Mikhailidis DP Elisaf M

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.16, 2008-11, pp. : 2741-2750

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rimonabant: a guide to its use in obese and overweight patients

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 23, Iss. 8, 2007-08 ,pp. : 5-8

Adis International

Access to resources Recommend Favorite

Cardiometabolic risk factors in T2DM improved by rimonabant

Inpharma, Vol. 1, Iss. 1655, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

By Kiortsis D.N. Millionis H. Bairaktari E. Elisaf M.S.

European Journal of Clinical Pharmacology, Vol. 56, Iss. 9-10, 2000-12 ,pp. : 631-635

Springer Publishing Company

Access to resources Recommend Favorite

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

By Gelfand Eli V Cannon Christopher P

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 307-315

Informa Healthcare

Access to resources Recommend Favorite

Rimonabant relieves obesity burden in overweight patients

Inpharma, Vol. 1, Iss. 1526, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite